Perioperative management in patients with risk for thrombosis
|
|
- Bernice Atkinson
- 7 years ago
- Views:
Transcription
1 Perioperative management in patients with risk for thrombosis Sabine Eichinger Dept. of Medicine I Medical University of Vienna, Austria
2 Perioperative Management Bleeding risk Thrombotic risk Stop antithrombotics Bridging
3 Atrial Fibrillation Risk of cerebral infarction CHADS 2 Risk/year Non surgical (%) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Kaatz, J Thromb Haemost 2010
4 Atrial Fibrillation Risk of cerebral infarction CHADS 2 Risk/year Non surgical (%) 30 days postoperative (%) ( ) 1.01 ( ) ( ) 1.62 ( ) ( ) 2.05 ( ) ( ) 2.63 ( ) ( ) 3.62 ( ) ( ) 3.65 ( ) ( ) 7.35 ( ) Kaatz, J Thromb Haemost 2010
5 Anticoagulation and perioperative management Low bleeding risk Tooth extraction Root canal procedures Small skin excisions Endoscopic procedures with low bleeding risk Cataract surgery Minor bleeding: OR 3.3 (95% CI ); Jamula, Thromb Res 2009 Perioorbital bleeding and retrobulbar anesthesia: 1/136 (<1%) Katz, Ophthalmology 2003 Dunn, Arch Intern Med 2003
6 Anticoagulation and perioperative management High bleeding risk Intracranial or intraspinal surgery Coronary artery bypass Major vascular surgery Major orthopedic surgery Major cancer surgery Reconstructive plastic surgery Urogenital surgery Colonpolypectomie (particularly > 1 cm Ø) Prostate- or kidney biopsy
7 Thromboembolic risk categories Thromboembolic Risk Atrial Fibrillation Mechanical Heart Valves Venous Thromboembolism High CHADS 2 5,6 Mitral valve Older aortic valve (caged-ball, tilting disk) Stroke/TIA < 3 mo VTE < 3 mo Moderate CHADS 2 3,4 Bileaflet aortic valve + risk factor VTE > 3-12 mo Low CHADS Bileaflet aortic valve w/o risk factor VTE > 12 mo Douketis, Blood 2011
8 Thromboembolic risk categories Thromboembolic Risk Bridging High YES Moderate Low NO Douketis, Blood 2011
9 Bridging Thromboembolic Risk Bridging High LMWH therapeutic Moderate Low LMWH therapeutic LMWH low dose none Douketis, Blood 2011
10 Anticoagulation and perioperative management Practical advice Do not stop VKA too early
11 Discontinuation of VKA PREOPERATIVE MANAGEMENT Stop warfarin Stop acenocoumarol THROMBOPROPHYLAXIS NO VKA Days P Check INR if < 1.5: surgery possible Check INR if >2.0: 6-10 mg vit. K p.o. Check INR if >2.0 (>2.5): check daily if <2.0 (<2.5): LMWH (except low thrombotic risk)
12 Anticoagulation and perioperative management Practical advice Do not stop VKA too early Last therapeutic dose of LMWH 24 h before surgery
13 Discontinuation of VKA POSTOPERATIVE MANAGEMENT THERAPEUTIC LMWH DOSE High/moderate THROMBOTIC RISK PROPHYLACTIC STOP LMWH IF INR >2.0 RESUME VKA DAYS 0P RESUME VKA Low THROMBOTIC RISK USUAL THROMBOPROPHYLAXIS STOP LMWH IF INR >2.0
14 Anticoagulation and perioperative management Practical advice Do not stop VKA too early Last therapeutic dose of LMWH 24 h before surgery Resume therapeutic LMWH not before 48 h postop.
15 Heparin bridging bleeding risk All patients N=224 Heart valves N=112 AFIB N=112 Major bleeding 15 (6.7%) 8 (7.1%) 7 (6.3%) intraoperative 8 (3.6%) 4 (3.6%) 4 (3.6%) <7 T postop. 5 (2.2%) 4 (3.6%) 1 (0.9%) Kovacs, Circulation 2004 Low bleeding risk N=542 High bleeding risk N=108 All patients N=650 Major bleeding 0.74% 1.85% 0.92% Douketis, Arch Intern Med 2004
16 Bridging bleeding risk Group TE Events % (95% Cl) Major Bleeding % (95% Cl) Overall Bleeding % (95% Cl) Bridged cohort 0.9% ( ) 4.2% ( ) 13.1% ( ) LMWH dose therapeutic prophylactic/ intermediate 0.4% ( ) 0.2% ( ) 3.2% ( ) 3.4% ( ) 13.6% ( ) 8.5% ( ) Nonbridged cohort 0.6% ( ) 0.9% ( ) 3.4% ( ) Siegal, Circulation 2012
17 Clinically significant device-pocket hematoma Birnie, N Engl J Med 2013
18 Anticoagulation and perioperative management Practical advice Do not stop VKA too early Last therapeutic dose of LMWH 24 h before surgery Resume therapeutic LMWH not before 48 h postop. LMWH bridging preoperatively only in patients at high thrombotic risk
19 Anticoagulation and perioperative management Practical advice Do not stop VKA too early Last therapeutic dose of LMWH 24 h before surgery Resume therapeutic LMWH not before 48 h postop. LMWH bridging preoperatively only in patients at high thrombotic risk VKA postoperative: start low - go slow
20 Perioperative Management D i r e c t or a l OP a n t i c o a g u l a n t s Stop Start
21 DOAC and perioperative management Low bleeding risk Do not stop DOAC Perform intervention at trough level OD dosing: halt morning dose until after intervention BID dosing: miss morning dose
22 Dabigatran, Apixaban Low bleeding risk day - 3 day - 2 day - 1 day 0 day + 1 day + 2 day + 3 Rivaroxaban day - 3 day - 2 day - 1 day 0 day + 1 day + 2 day + 3 P R E O P E R A T I V E P O S T O P E R A T I V E
23 Dabigatran perioperative management Elective surgery/interventions Renal function (CrCl in ml/min) Half life Last intake before surgery High bleeding risk or major surgery Standard risk 80 ~ 13 h >48 h >24 h 50 to < 80 ~ 15 h >72 h >36 h 30 to < 50 ~ 18 h >96 h >48 h EHRA guidelines, Heidbuchel, Eur Heart J 2013
24 Rivaroxaban, Apixaban perioperative management Elective surgery/interventions Renal function (CrCl in ml/min) Last intake before surgery High bleeding risk or major surgery Standard risk 80 >48 h >24 h 50 to < 80 >48 h >24 h 30 to < 50 >48 h >24 h 15 to < 30 >48 h >36 h EHRA guidelines, Heidbuchel, Eur Heart J 2013
25 Rivaroxaban perioperative management High bleeding risk day - 3 day - 2 day - 1 day 0 day + 1 day + 2 day + 3 P R E O P E R A T I V E P O S T O P E R A T I V E usual thromboprophylaxis
26 Direct oral anticoagulants Restart after surgery Not licensed for postoperative thromboprophylaxis except for elective hip/knee replacement. Immediate and complete hemostasis resume DOAC after 6-8 hours. Maximum concentration within 2-3 h. Start therapeutic dose not before h postop. Use LMWH at prophylactic dose until safe to use therapeutic dose.
27 RE-ly dabigatran in atrial fibrillation Periprocedural bleeding D110 D150 Warfarin % Cases minor major reoperation transfusion 10 0 minor major reoperation transfusion Healey, Circulation 2012
28 RE-ly dabigatran in atrial fibrillation Periprocedural thromboembolism % Cases ,8 0,6 0,4 0,2 D110 D150 Warfarin CV death stroke 0 CV death stroke Healey, Circulation 2012
29 Direct oral anticoagulants perioperative management Practical advice Prescribe DOAC exactly as licensed Check contraindications Dose according to indication an renal function check renal function and ensure proper diuresis Collect standardized bleeding and thrombotic history Lower dose in case of higher bleeding risk Use platelet function inhibitors together with DOAC with caution Avoid long acting NSARs No preoperative heparin bridging
CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4
LAMC Department of Pharmacy Services: ANTICOAGULATION: Surgical Intervention Table 1: Classification of Surgical interventions according to bleeding risk t required to discontinue anticoagulation Dental
More informationPerioperative Anticoagulation Management. Tony Ochoa, MD, FACC
Perioperative Anticoagulation Management Tony Ochoa, MD, FACC Interrupting Anticoagulation: To Bridge or Not? Peri-operative is most common reason Injury/Acute internal bleeding (not discussed) Atrial
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationHow To Manage An Anticoagulant
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
More informationTo Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC
To Bridge or Not to Bridge Periop Anticoagulation Management Don Weinshenker, MD Ambulatory Care Denver VAMC Financial Disclosure Information Nothing to report Periop AC Management Chronically anti-coagulated
More informationCoagulation issues and bridging. Joost van Veen Consultant Haematologist - STHFT
Coagulation issues and bridging Joost van Veen Consultant Haematologist - STHFT new oral anticoagulants NOAC New oral anticoagulants NOAC Novel oral anticoagulants NOAC Non vitamin K oral anticoagulants
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationLovenox Bridging Who needs it? Practical Guidelines
Lovenox Bridging Who needs it? Practical Guidelines Edward Perlstein, MD Tri-City Cardiology Consultants Faculty Disclosure I Have No Financial Interest to Disclose James D. Douketis MD, FRCP(C) Dept.
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationPeriprocedural Management of Direct Oral Anticoagulants (DOACs)
+ Periprocedural Management of Direct Oral Anticoagulants (DOACs) Mary-Margaret Keating MD FRCPC Hematology Assistant Professor, Dalhousie University Halifax, NS Canada + Presenter Disclosures Faculty/Presenter
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationManaging Anticoagulation for Atrial Fibrillation 2015
Managing Anticoagulation for Atrial Fibrillation 2015 Vikranth Gongidi, DO FACC FACOI Indian River Medical Center Vero Beach, FL Atrial Fibrillation Background and Guidelines Decisions to anticoagulate
More informationANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE
ANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE Jamie N. Nadler, M.D. Assistant Professor of Medicine State University of New York at Buffalo Department of medicine Division
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationNWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban.
NWMIC Medicines FAQ New oral anticoagulants (NOACs) and management of dental patients - Date prepared: May 2013, updated November 2013 Summary In primary care; Consider liaising with the local hospital
More informationBridging anticoagulation: the peri-procedural management of patients on oral anticoagulants (excluding neurosurgery)
Barnsley Hospital NHS Foundation Trust Bridging anticoagulation: the peri-procedural management of patients on oral anticoagulants (excluding neurosurgery) Reproduced and Adapted from the Sheffield Bridging
More informationUse of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationBridging Anticoagulation: The Peri-Procedural Management of Patients on Oral Anticoagulants
Bridging Anticoagulation: The Peri-Procedural Management of Patients on Oral Anticoagulants Dr Stuti Kaul- Consultant Haematologist Dr Youssef Sorour- Consultant Haematologist Lee Wilson- Consultant Pharmacist
More informationNHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY
MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY The scope of this guideline is to simplify the management of patients on oral anticoagulation undergoing major and minor surgery.
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationPerioperative Bridging in Atrial Fibrillation: Is it necessary?
Perioperative Bridging in Atrial Fibrillation: Is it necessary? Jason B. Thompson M.D., Ph.D. August 29, 2015 2015 NCVH Birmingham Hypothesis: When bridging, risk of bleeding < risk systemic embolism (SE).
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationNOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST
NOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST NGAIRE IS 70 YEARS OLD AND IN AF. SHE HAS NO MURMURS, NORMAL BLOOD PRESSURE, EGFR OF 65ML/MIN AND NO SIGNIFICANT PAST MEDICAL HISTORY. REGARDING
More informationManagement of Antithrombotics with Procedures. Jordan Weinstein, MD
Management of Antithrombotics with Procedures Jordan Weinstein, MD Presenter Disclosure Information Cardiology Update 2013 I have no relevant financial interest and/or arrangement with industry. Novel
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationPeriprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline. Cover Sheet
Periprocedural Anticoagulation Adult Inpatient and Ambulatory Clinical Practice Guideline Cover Sheet Target Population: Inpatient and Ambulatory Adult Patients CPG Contact: Name: Sara Shull, PharmD, MBA,
More informationGREEN ZONE No action needed. You are doing great
Blood Thinner Safety Plan: Which zone are you in? Check your zone often to stay healthy and safe The name of my blood thinner is: (CIRCLE the medications you take): Coumadin (warfarin) Pradaxa (dabigatran)
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationUSE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationTime in the Therapeutic Range 2015-02-11. Conflict Disclosure Information. 'As The Clot Thickens' A NOAC (Novel Anticoagulant Update)
Conflict Disclosure Information Kevin J. Pistawka NOAC S New Oral Anti-Coagulants Dr. K. Pistawka - KGH FINANCIAL DISCLOSURE Grants/Research Support: None Research Trial involvment RELY, RELYABLE Speakers
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationBridging the Gap: How to Transition from the NOACs to Warfarin
Bridging the Gap: How to Transition from the NOACs to April 24 th 2015 UAN: 0048-0000-15-034-L01-P Amanda Styer, Pharm.D. Marion General Hospital, OhioHealth Objectives: 1. Review labeling regarding transition
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More information9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban
Identify the FDA approved direct oral anticoagulants (DOACs) Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services Distinguish the differences in the dosing of DOACs for various indications Describe
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationNo Relevant Financial Disclosures
A New Era of Blood Thinners: Target Specific Oral Anticoagulants No Relevant Financial Disclosures Kiran Lassi, MD Agenda Case Scenarios Types of new anticoagulants Mechanism Of Action FDA approval status
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationAnticoagulation Management Insanity: doing the same thing over and over again and expecting different results. Case 1
2011 MFMER slide-1 Anticoagulation Management Insanity: doing the same thing over and over again and expecting different results Fadi Elias Shamoun, MD Mayo Clinic in Arizona Albert Einstein Anticoagulation
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
More informationNIL. Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts. Approach. Approach. 06-Nov-14
Stroke Prevention in Atrial Fibrillation: Commencing Non- Oral Anticoagulants in GP setting Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts Disclosures NIL Classification
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationAntithrombotic therapy
Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be
More informationDocument Newer Anticoagulants and Elective Procedures Version Version 1.0 (April 2015) Dr Phil Robson, Consultant Haematologist Review April 2018
Document Newer Anticoagulants and Elective s Version Version 1.0 April 2015) Author Dr Phil Robson, Consultant Haematologist Review April 2018 Elective Surgery in Adults on Novel Anticoagulants NOACs)
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationUse of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationANTICOAGULATION IN ATRIAL FIBRILLATION. Heather Kertland St Michael s Hospital University of Toronto
ANTICOAGULATION IN ATRIAL FIBRILLATION Heather Kertland St Michael s Hospital University of Toronto Susan A 73 year old female admitted to the general medicine ward with pneumonia. She had been feeling
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationPeri-Operative Anticoagulation Bridging Guidelines
Peri-Operative Anticoagulation Bridging Guidelines Anticoagulation Bridging Based on Thrombotic Risk and Indication Risk of TE Mechanical Valves Mechanical Valve Bridge Therapy High Any mitral prosthesis
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationReducing Adverse Drug Events With Anti Coagulation Clinics. McFarland Clinic. McFarland Protime Clinic 09/05/12
Reducing Adverse Drug Events With Anti Coagulation Clinics Dr. Donald Skinner, MD McFarland Clinic 182 Physicians (149 Shareholders) 40 Mid Level Providers 13 Administrators/Executive Directors 1,200 Support
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationObjectives. Patient Background. Transitioning a Patient To & From a New Oral Anticoagulant
Objectives Transitioning a Patient To & From a New Oral Anticoagulant How to switch from warfarin to rivaroxaban Discuss the Medicare donut hole How to switch from rivaroxaban to warfarin Home INR monitoring
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationEmerging Challenges In Primary Care: 2015
Care Se'ng Emerging Challenges In Primary Care: 2015 Preventing Stroke in Patients with Atrial Fibrillation: New Concepts and Controversies 1 Faculty Elizabeth A. Jackson, MD, MPH Associate Professor of
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationCardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationPractical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준
Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Contents Converting to/from rivaroxaban Measuring levels of rivaroxaban Patients potentially at higher risk of bleeding Renal
More informationInpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationPRACTICAL MANAGEMENT OF ANTICOAGULATION
PRACTICAL MANAGEMENT OF ANTICOAGULATION THE BLOOD THINS AND THE PLOT THICKENS Juliann Horne, PharmD PGY2 Pharmacy Resident in Ambulatory Care UNM College of Pharmacy jmhorne@salud.unm.edu Disclosure No
More information